← Leaderboards
Jolanta Grembecka
University Of Michigan At Ann Arbor
$12,187,788
Attributed
$13,162,464
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,162,464 · 9
By mechanism
R01$13,113,165 · 7
R03$49,299 · 2
Top collaborators
- Arul M Chinnaiyan5 shared
- Tomasz Cierpicki1 shared
- John Pius Dalton1 shared
- Donald L Gardiner1 shared
- Katharine Ruth Trenholme1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Juanita L Merchant$22,602,061
- Tomasz Cierpicki$10,333,927
- Rosemary Rochford$6,564,789
- Paul Michael Jenkins$1,818,635
- Steven Richard Meshnick$14,282,524
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsIn VivoSmall MoleculeNovel TherapeuticsLeukemiaPropertyPharmaceutical PreparationsLeadComplexBindingGenesMeninReportingSmall Molecule InhibitorMetabolicDrug KineticsDesignPharmaceutical ChemistryToxic EffectMouse ModelAnalogStructureClinical TrialsBase
Grant awards (32)
Overcoming resistance to menin patient mutations in leukemia$640,135
R01 · FY2025 · CA · contact PI
Targeting Menin in Acute Leukemia with Upregulated HOX Genes$633,462
R01 · FY2025 · CA · contact PI
Screening for inhibitors of NSD3 as a treatment for lung cancer$481,033
R01 · FY2025 · CA · contact PI
Targeting Menin in Acute Leukemia with Upregulated HOX Genes$601,790
R01 · FY2024 · CA · contact PI
Development of ASH1L inhibitors for acute leukemia$544,236
R01 · FY2024 · CA · contact PI
Screening for inhibitors of NSD3 as a treatment for lung cancer$486,735
R01 · FY2024 · CA · contact PI
Targeting Menin in Acute Leukemia with Upregulated HOX Genes$633,462
R01 · FY2023 · CA · contact PI
Development of ASH1L inhibitors for acute leukemia$563,962
R01 · FY2023 · CA · contact PI
Screening for inhibitors of NSD3 as a treatment for lung cancer$529,475
R01 · FY2023 · CA · contact PI
Development of ASH1L inhibitors for acute leukemia$563,962
R01 · FY2022 · CA · contact PI
Development of ASH1L inhibitors for acute leukemia$570,861
R01 · FY2021 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$372,809
R01 · FY2021 · CA · contact PI
Development of ASH1L inhibitors for acute leukemia$568,956
R01 · FY2020 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$372,809
R01 · FY2020 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$368,224
R01 · FY2020 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$362,030
R01 · FY2019 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$361,624
R01 · FY2019 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$378,124
R01 · FY2018 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$372,258
R01 · FY2018 · CA · contact PI
Targeting protein-protein interactions of Bmi1 oncoprotein$319,688
R01 · FY2018 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$386,776
R01 · FY2017 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$384,355
R01 · FY2017 · CA · contact PI
Targeting protein-protein interactions of Bmi1 oncoprotein$319,688
R01 · FY2017 · CA · contact PI
Targeting the MLL complex in Castration Resistant Prostate Cancer$392,750
R01 · FY2016 · CA · contact PI
Targeting protein-protein interactions of Bmi1 oncoprotein$319,688
R01 · FY2016 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$322,663
R01 · FY2015 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$312,981
R01 · FY2014 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$303,301
R01 · FY2013 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$322,664
R01 · FY2012 · CA · contact PI
Development of novel anti-leukemia agents targeting the menin-MLL interaction$322,664
R01 · FY2011 · CA · contact PI
Screening for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leuke$24,999
R03 · FY2008 · MH · contact PI
Identification of Inhibitors of the Plasmodium Falciparum M18 Metalloprotease$24,300
R03 · FY2008 · MH